October 2025 in “Clinical Chemistry” Juniperus communis extract enhances the effectiveness of oral cancer treatment when combined with chemotherapy.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
7 citations
,
March 2023 in “Lasers in Surgery and Medicine” Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.
26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
508 citations
,
June 2009 in “Current drug metabolism” Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
48 citations
,
January 2020 in “Cochrane Database of Systematic Reviews” Serlopitant may help reduce itch, but more research is needed.
February 2024 in “Indian Journal of Chemistry” Compound N4 effectively kills breast cancer cells and compounds N2 and N3 have strong antibacterial and antifungal properties.
3 citations
,
April 2021 in “Biomolecules & Therapeutics” The protein ER71/ETV2 helps regrow hair after chemotherapy by improving the growth of new blood vessels.
1 citations
,
November 2025 in “Journal of the American Academy of Dermatology” 48 citations
,
February 1999 in “PubMed” Finasteride, a drug, can block the seizure-preventing effects of a hormone called progesterone in mice.
1 citations
,
December 2021 in “JAAD case reports” A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.
17 citations
,
September 2022 in “Biomaterials Research” The film-trigger applicator improves microneedle skin delivery and drug efficiency using simple finger force.
June 2026 in “International Journal of Drug Delivery Technology” Fast-dissolving nifedipine tablets were successfully developed for better oral delivery.
December 2025 in “Drug Design Development and Therapy” Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
47 citations
,
September 1995 in “British Journal of Dermatology” Diphencyprone therapy for hair loss can cause vitiligo.
47 citations
,
December 2019 in “Frontiers in immunology” A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.
7 citations
,
March 2023 in “Arabian Journal of Chemistry” Cepharanthine may help treat COVID-19 by targeting multiple pathways.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
11 citations
,
September 2008 in “European Journal of Drug Metabolism and Pharmacokinetics” Finasteride helps reduce pain and inflammation in animals.
3 citations
,
July 2018 in “Biomedicine & pharmacotherapy” Paeoniflorin protects brain cells by involving a specific protein and neurosteroids.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
September 2004 in “Inpharma Weekly” 21 citations
,
March 2021 in “Molecules” The new formulation greatly improved quercetin absorption in rats.
84 citations
,
December 2018 in “Genetics in Medicine” Pegvaliase is recommended for treating adults with phenylketonuria.
December 2022 in “International Journal of Molecular Sciences” Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.
January 2024 in “Pediatric rheumatology online journal” Early genetic testing and JAK inhibitors can help treat systemic inflammation in SAVI patients.